SIRPA and cancer: Engineered exosomes that antagonize the interaction between CD47 and SIRPα promote intensive T cell infiltration in syngeneic mouse models of cancer [279], indicating that exosome-mediated immunotherapy targeting the CD47/SIRPα axis is one of the most promising new strategies for immuno-oncology.